KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biogen (BIIB) Non Operating Income (2016 - 2022)

Biogen has reported Non Operating Income over the past 14 years, most recently at -$263.3 million for Q1 2022.

  • Quarterly results put Non Operating Income at -$263.3 million for Q1 2022, up 48.06% from a year ago — trailing twelve months through Mar 2022 was -$851.9 million (down 867.48% YoY), and the annual figure for FY2025 was -$305.6 million, up 11.06%.
  • Non Operating Income for Q1 2022 was -$263.3 million at Biogen, down from -$182.1 million in the prior quarter.
  • Over the last five years, Non Operating Income for BIIB hit a ceiling of $683.5 million in Q4 2020 and a floor of -$506.9 million in Q1 2021.
  • Median Non Operating Income over the past 5 years was -$41.0 million (2018), compared with a mean of -$45.1 million.
  • Biggest five-year swings in Non Operating Income: tumbled 472.17% in 2019 and later surged 1486.41% in 2020.
  • Biogen's Non Operating Income stood at -$28.6 million in 2018, then crashed by 72.38% to -$49.3 million in 2019, then surged by 1486.41% to $683.5 million in 2020, then tumbled by 126.64% to -$182.1 million in 2021, then plummeted by 44.59% to -$263.3 million in 2022.
  • The last three reported values for Non Operating Income were -$263.3 million (Q1 2022), -$182.1 million (Q4 2021), and -$502.9 million (Q3 2021) per Business Quant data.